Cargando…
Acute Myocardial Infarction in Patients with Hereditary Thrombophilia—A Focus on Factor V Leiden and Prothrombin G20210A
Factor V (FV) Leiden and prothrombin G20210A are the most common hereditary thrombophilias. While their role in venous thromboembolism is well known, there are still uncertainties regarding their relationship with arterial thrombotic events, especially coronary ones. Our research, based on an in-dep...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300874/ https://www.ncbi.nlm.nih.gov/pubmed/37374153 http://dx.doi.org/10.3390/life13061371 |
_version_ | 1785064679360430080 |
---|---|
author | Badescu, Minerva Codruta Butnariu, Lăcrămioara Ionela Costache, Alexandru Dan Gheorghe, Liliana Seritean Isac, Petronela Nicoleta Chetran, Adriana Leancă, Sabina Andreea Afrăsânie, Irina Duca, Ștefania-Teodora Gorduza, Eusebiu Vlad Costache, Irina Iuliana Rezus, Ciprian |
author_facet | Badescu, Minerva Codruta Butnariu, Lăcrămioara Ionela Costache, Alexandru Dan Gheorghe, Liliana Seritean Isac, Petronela Nicoleta Chetran, Adriana Leancă, Sabina Andreea Afrăsânie, Irina Duca, Ștefania-Teodora Gorduza, Eusebiu Vlad Costache, Irina Iuliana Rezus, Ciprian |
author_sort | Badescu, Minerva Codruta |
collection | PubMed |
description | Factor V (FV) Leiden and prothrombin G20210A are the most common hereditary thrombophilias. While their role in venous thromboembolism is well known, there are still uncertainties regarding their relationship with arterial thrombotic events, especially coronary ones. Our research, based on an in-depth analysis of the available literature, provides up-to-date information on the relationship between FV Leiden and prothrombin G20210A and acute myocardial infarction. FV Leiden and prothrombin G20210A screening should be implemented only in select cases, such as acute coronary syndrome in young individuals and/or in the absence of traditional cardiovascular risk factors and/or in the absence of significant coronary artery stenosis at angiography. Their identification should be followed by the implementation of optimal control of modifiable traditional cardiovascular risk factors to reduce the risk of recurrent events and genotyping and genetic counseling of all family members of affected cases for proper prophylaxis. An extended dual antiplatelet therapy (DAPT) may be considered, given the lower risk of bleeding under DAPT conferred by FV Leiden. |
format | Online Article Text |
id | pubmed-10300874 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103008742023-06-29 Acute Myocardial Infarction in Patients with Hereditary Thrombophilia—A Focus on Factor V Leiden and Prothrombin G20210A Badescu, Minerva Codruta Butnariu, Lăcrămioara Ionela Costache, Alexandru Dan Gheorghe, Liliana Seritean Isac, Petronela Nicoleta Chetran, Adriana Leancă, Sabina Andreea Afrăsânie, Irina Duca, Ștefania-Teodora Gorduza, Eusebiu Vlad Costache, Irina Iuliana Rezus, Ciprian Life (Basel) Review Factor V (FV) Leiden and prothrombin G20210A are the most common hereditary thrombophilias. While their role in venous thromboembolism is well known, there are still uncertainties regarding their relationship with arterial thrombotic events, especially coronary ones. Our research, based on an in-depth analysis of the available literature, provides up-to-date information on the relationship between FV Leiden and prothrombin G20210A and acute myocardial infarction. FV Leiden and prothrombin G20210A screening should be implemented only in select cases, such as acute coronary syndrome in young individuals and/or in the absence of traditional cardiovascular risk factors and/or in the absence of significant coronary artery stenosis at angiography. Their identification should be followed by the implementation of optimal control of modifiable traditional cardiovascular risk factors to reduce the risk of recurrent events and genotyping and genetic counseling of all family members of affected cases for proper prophylaxis. An extended dual antiplatelet therapy (DAPT) may be considered, given the lower risk of bleeding under DAPT conferred by FV Leiden. MDPI 2023-06-12 /pmc/articles/PMC10300874/ /pubmed/37374153 http://dx.doi.org/10.3390/life13061371 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Badescu, Minerva Codruta Butnariu, Lăcrămioara Ionela Costache, Alexandru Dan Gheorghe, Liliana Seritean Isac, Petronela Nicoleta Chetran, Adriana Leancă, Sabina Andreea Afrăsânie, Irina Duca, Ștefania-Teodora Gorduza, Eusebiu Vlad Costache, Irina Iuliana Rezus, Ciprian Acute Myocardial Infarction in Patients with Hereditary Thrombophilia—A Focus on Factor V Leiden and Prothrombin G20210A |
title | Acute Myocardial Infarction in Patients with Hereditary Thrombophilia—A Focus on Factor V Leiden and Prothrombin G20210A |
title_full | Acute Myocardial Infarction in Patients with Hereditary Thrombophilia—A Focus on Factor V Leiden and Prothrombin G20210A |
title_fullStr | Acute Myocardial Infarction in Patients with Hereditary Thrombophilia—A Focus on Factor V Leiden and Prothrombin G20210A |
title_full_unstemmed | Acute Myocardial Infarction in Patients with Hereditary Thrombophilia—A Focus on Factor V Leiden and Prothrombin G20210A |
title_short | Acute Myocardial Infarction in Patients with Hereditary Thrombophilia—A Focus on Factor V Leiden and Prothrombin G20210A |
title_sort | acute myocardial infarction in patients with hereditary thrombophilia—a focus on factor v leiden and prothrombin g20210a |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300874/ https://www.ncbi.nlm.nih.gov/pubmed/37374153 http://dx.doi.org/10.3390/life13061371 |
work_keys_str_mv | AT badescuminervacodruta acutemyocardialinfarctioninpatientswithhereditarythrombophiliaafocusonfactorvleidenandprothrombing20210a AT butnariulacramioaraionela acutemyocardialinfarctioninpatientswithhereditarythrombophiliaafocusonfactorvleidenandprothrombing20210a AT costachealexandrudan acutemyocardialinfarctioninpatientswithhereditarythrombophiliaafocusonfactorvleidenandprothrombing20210a AT gheorgheliliana acutemyocardialinfarctioninpatientswithhereditarythrombophiliaafocusonfactorvleidenandprothrombing20210a AT seriteanisacpetronelanicoleta acutemyocardialinfarctioninpatientswithhereditarythrombophiliaafocusonfactorvleidenandprothrombing20210a AT chetranadriana acutemyocardialinfarctioninpatientswithhereditarythrombophiliaafocusonfactorvleidenandprothrombing20210a AT leancasabinaandreea acutemyocardialinfarctioninpatientswithhereditarythrombophiliaafocusonfactorvleidenandprothrombing20210a AT afrasanieirina acutemyocardialinfarctioninpatientswithhereditarythrombophiliaafocusonfactorvleidenandprothrombing20210a AT ducastefaniateodora acutemyocardialinfarctioninpatientswithhereditarythrombophiliaafocusonfactorvleidenandprothrombing20210a AT gorduzaeusebiuvlad acutemyocardialinfarctioninpatientswithhereditarythrombophiliaafocusonfactorvleidenandprothrombing20210a AT costacheirinaiuliana acutemyocardialinfarctioninpatientswithhereditarythrombophiliaafocusonfactorvleidenandprothrombing20210a AT rezusciprian acutemyocardialinfarctioninpatientswithhereditarythrombophiliaafocusonfactorvleidenandprothrombing20210a |